Weight loss

Pills
#MHRA #Obesity #UK #Weight loss

UK patients to benefit from approval of weight loss tablet  

UK patients will soon have access to a weight loss tablet following a landmark approval by the Medicines and Healthcare products Regulatory Agency (MHRA).  The body has approved oral Wegovy, which could be rolled out to as many as 100,000 patients living in the UK.  Research from healthcare company Simple… Read More

#News #Regulatory

#Cancer research #Clinical trial #Drug discovery #Francis Crick Institute #Funding #Genetic profiling #GLP-1 #Lung cancer #MHRA #National Institute for Health and Care Research #Obesity #Oncology #Rare disease #Regulatory #The Royal Marsden NHS Foundation Trust #University College London #Weight loss

DDW Highlights: 16 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, new research showed anti-IL-1β drugs could prevent lung cancer. Elsewhere, the… Read More

#Podcasts

#Cancer research #Clinical trial #Drug discovery #Funding #Genetic profiling #GLP-1 #Lung cancer #MHRA #National Institute for Health and Care Research #Obesity #Oncology #Rare disease #Regulatory #The Francis Crick Institute #The Royal Marsden NHS Foundation Trust #University College London #Weight loss

This week in Drug Discovery (8 – 12 June) 

News round-up for 8 – 12 June by Bruno Quinney, Content Team at DDW.  This week, new research suggests anti-IL-1β drugs could prevent lung cancer. Elsewhere, the UK is set to benefit from specialised blood tests and funding for researchers.   The top stories:   … Read More

#News

#GLP-1 #Obesity #Weight loss

Obesity therapies could offer benefits beyond weight loss 

MetaVia has presented data showing its obesity therapies could offer broader benefits than weight loss alone.  DA-1726, a novel dual agonist targeting glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), reduced body weight by 9.1% at Day 54 in a Phase I trial, as well as reducing waist… Read More

#News

#Boehringer Ingelheim #GLP-1 #Obesity #Weight loss

GLP-1 reduces liver fat by 63%, trial results show 

The glucagon/GLP-1 dual agonist survodutide could reduce liver fat by 63%, results show.  Boehringer Ingelheim reported positive results from two Phase III trials, which demonstrated patients lost 63% liver fat, 34% visceral fat and showed minimal lean mass change at the highest dose.  The results demonstrate survodutide’s potential to… Read More

#News

#AI #Cancer research #Cervical cancer #Clinical trial #Colorectal cancer #Genetics / genomics #Head and neck cancer #MHRA #Obesity #Pistoia Alliance #Precision medicine #University College London #University of Cambridge #Weight loss

DDW Highlights: 9 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a cancer drug demonstrated it could reduce tumours by as much as… Read More

#Podcasts

#Obesity #Preclinical investigations #Verdiva Bio #Weight loss

Verdiva Bio presents preclinical data on obesity treatments

Verdiva Bio has announced new preclinical data for VRB-103, a once-weekly oral amylin receptor-selective amylin analog, and VRB-104, a unimolecular amylin and GLP-1 receptor dual agonist.   The data were presented in poster sessions at the American Diabetes Association (ADA), taking place 5-8 June in New Orleans, Louisiana,… Read More

#News

#AI #Cancer research #Cervical cancer #Clinical trial #Colorectal cancer #Genetics / genomics #Head and neck cancer #MHRA #Obesity #Pistoia Alliance #Precision medicine #University College London #University of Cambridge #Weight loss

This week in Drug Discovery (1 June – 5 June) 

News round-up for 1 June – 5 June by Bruno Quinney, Content Team at DDW.  This week, a cancer drug has demonstrated it could reduce tumours by as much as 55%. Elsewhere, AI has been a recurrent theme in both clinical trials and drug development.   The top stories:… Read More

#News

Patient injects Ozempic
#Obesity #University College London #University of Cambridge #Weight loss

Obesity drugs could widen health inequalities, warn UK researchers

Without affordable, healthy food and appropriate support, obesity drugs such as semaglutide and tirzepatide could widen health inequalities, say researchers at UCL and the University of Cambridge.  In a correspondence published in Nature Medicine, the researchers argue that while incretin-based therapies… Read More

#News

#Eli Lilly #GLP-1 #Obesity #Phase III trial #Weight loss

Lilly’s new triple agonist delivers weight loss equal to bariatric surgery

Eli Lilly has announced positive topline results from TRIUMPH-1, a Phase III clinical trial evaluating the efficacy and safety of retatrutide, a GIP, GLP-1,and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes.   At 80 weeks,… Read More

#News

#GLP-1 #Mounjaro #Obesity #Ozempic #Weight loss

Weight-loss drugs’ challenge to pharma’s safety infrastructure

For the huge commercial success represented by GLP-1 agonists such as Mounjaro and Ozempic, particularly now in the context of treating obesity, they also present an operational nightmare for companies. That's as  volumes of adverse events threaten to swamp existing safety workflows. Qinecsa’s Daniel O’Keeffe assesses the scale of the problem.  The success of Glucagon-Like Peptide-1 (GLP-1) receptor agonists as modern weight-loss solutions has yet to… Read More

#Exclusive Content #Opinion

Weight loss concept
#Clinical trial #Obesity #Weight loss

Drug delivers 16% weight loss results in Phase III trial 

A new drug could lead to 16% weight loss in patients and improve metabolic health, Phase III results show.  Survodutide, a dual glucagon/GLP‑1 receptor agonist, has been developed by pharmaceutical company Boehringer Ingelheim for the treatment of adults living with obesity or overweight, without type 2 diabetes. … Read More

#News

#Antibody drug conjugate (ADC) #Cytokine Release Syndrome (CRS) #Diabetes #Eli Lilly #GLP-1 #Idiopathic pulmonary fibrosis #Lung disease #Mergers and acquisitions #MHRA #Obesity #Poolbeg Pharma #Respiratory #Weight loss

DDW Highlights: 28 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, an obesity drug proved it could improve liver health independent of weight… Read More

#Podcasts

#Antibody drug conjugate (ADC) #Cytokine Release Syndrome (CRS) #Diabetes #Eli Lilly #GLP-1 #Idiopathic pulmonary fibrosis #Lung disease #Mergers and acquisitions #MHRA #Obesity #Poolbeg Pharma #Respiratory #Weight loss

This week in Drug Discovery (20 – 24 April) 

News round-up for 20 – 24 April by Bruno Quinney, Content Team at DDW.  This week, an obesity drug could improve liver health independent of weight loss. Elsewhere, Lilly is back in the news for both its type 2 diabetes drug and the company’s latest acquisition.  The top stories:   … Read More

#News

Human liver
#Diabetes #GLP-1 #Obesity #Weight loss

GLP-1 improves liver health independent of weight loss

Researchers at Sinai Health have found that semaglutide acts directly on a subset of liver cells to improve organ function, and does so independently of weight loss.   The finding challenges long-held assumptions about how GLP-1 medicines work in the liver and could reshape how physicians treat metabolic… Read More

#Editor's Choice #News

Cardiovascular system
#Diabetes #Eli Lilly #Obesity #Phase III trial #Weight loss

Lilly publishes data confirming Foundayo’s safety profile

Eli Lilly has shared positive topline results from the Phase III ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron), compared to insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk.   ACHIEVE-4, the largest and longest study of Foundayo… Read More

#News